9 research outputs found
Characterization of an Nmr Homolog That Modulates GATA Factor-Mediated Nitrogen Metabolite Repression in Cryptococcus neoformans
Nitrogen source utilization plays a critical role in fungal development, secondary metabolite production and pathogenesis. In both the Ascomycota and Basidiomycota, GATA transcription factors globally activate the expression of catabolic enzyme-encoding genes required to degrade complex nitrogenous compounds. However, in the presence of preferred nitrogen sources such as ammonium, GATA factor activity is inhibited in some species through interaction with co-repressor Nmr proteins. This regulatory phenomenon, nitrogen metabolite repression, enables preferential utilization of readily assimilated nitrogen sources. In the basidiomycete pathogen Cryptococcus neoformans, the GATA factor Gat1/Are1 has been co-opted into regulating multiple key virulence traits in addition to nitrogen catabolism. Here, we further characterize Gat1/Are1 function and investigate the regulatory role of the predicted Nmr homolog Tar1. While GAT1/ARE1 expression is induced during nitrogen limitation, TAR1 transcription is unaffected by nitrogen availability. Deletion of TAR1 leads to inappropriate derepression of non-preferred nitrogen catabolic pathways in the simultaneous presence of favoured sources. In addition to exhibiting its evolutionary conserved role of inhibiting GATA factor activity under repressing conditions, Tar1 also positively regulates GAT1/ARE1 transcription under non-repressing conditions. The molecular mechanism by which Tar1 modulates nitrogen metabolite repression, however, remains open to speculation. Interaction between Tar1 and Gat1/Are1 was undetectable in a yeast two-hybrid assay, consistent with Tar1 and Gat1/Are1 each lacking the conserved C-terminus regions present in ascomycete Nmr proteins and GATA factors that are known to interact with each other. Importantly, both Tar1 and Gat1/Are1 are suppressors of C. neoformans virulence, reiterating and highlighting the paradigm of nitrogen regulation of pathogenesis
A Strategic Thinking of the Issues in Cost Management of FB Real Estate Company
æèŠ èźșæç»ćFBæżć°äș§ć
ŹćžćŒćéĄčçźéć°çäž»èŠéźéąïŒćŠäœéæ©éĄčçźćŒćçææŹçźĄçæç„仄è·ćææŹç«äșäŒćżïŒææŹçźĄçææäžäœłçéźéąïŒćŠææŹæ žçźæ°æźäžć祟äžèœćæ¶ćæ éĄčçźäș§ćçææŹç¶ć”ăéĄčçźćŒćéąçźäžćźé
æŻćșć·źćŒć€§ăäș§ćçææŹäžć©æ¶Šäžæž
æ„ăéĄčçźéŽææŹäžćŻæŻăææŹçźĄçäžèœćæ¶ćŻčćžćșććèżèĄè°æŽćäŒäžć©æ¶Šèą«äŸ”èçææŹć€±æ§éźéąćŠäœè§ŁćłïŒæäčćŻčćŒć°éĄčçźćŒćèżèĄææŹæ§ć¶ćéŁé©çźĄçïŒææ ·ćæ°çźĄçéćŻčæżć°äș§ææŹçźĄçççéŸéźéąć±ćŒæç„ćæç 究ïŒéèżćŻčè§Łćłéźéąççžć
łć çŽ ćæćŸćșè§ŁćłæčæĄïŒćšæéĄčçźćŒćäžèżèĄćșçšććŸæć仄éȘèŻć
¶ćŻèĄæ§ă èźșæ仄æéĄčçźćŒćéćŻčææŹçźĄçäžććšççéŸéźéąïŒä»„äŒäžææŹæç„知çæčæłçâäșććææł...Abstract This article is mainly focused on the following topics of FB Real Estate Company: how to obtain the competitive advantage of project management by carrying on effective cost management strategies? How to change the situation of ineffective cost management, such as the data can't reflect the cost of the project accurately and there is a huge gap between the project's budget and actual...ćŠäœïŒć·„ć知ççĄćŁ«éąçł»äžäžïŒçźĄçćŠéąé«çș§ç»çæèČäžćżïŒEMBAéĄčçźïŒ_é«çș§çźĄçäșșćć·„ć知ççĄćŁ«(EMBA)ćŠć·ïŒX200715612
Analysis and Suggestions for Business Model of eBayEachnet
EBAYæè¶Łçœćæ·ćźçœæŻçźćäžćœç”ćććĄäžç»ćžžèą«æćç䞀äžȘćŻčæă2002ćčŽæ¶ïŒEBAYæè¶ŁæŸç»äžæçŹç§ïŒäœćšæ·ćźçœćææçœçç«äșäžïŒèż
é䞧怱ćžćșéąć
ć°äœïŒćžćș仜éąéæ„猩ć°ïŒćč¶ç»äșäžTOMéćąæéć
Źćžäžć±çTOMćšçșżæç«äșćè„ć
Źćžă æŹæäž»èŠèżçšçżćć„ææçăćäžæšĄćŒćæ°ăçèźșïŒä»„ćè„ć
Źćžçæç«äžșç 究æȘæąæ¶éŽïŒć°èŻæç€șăćæăè§ŁéEBAYæè¶ŁććĄæšĄćŒéćŻčäžćœć€§éćžćșèèšććšçäžè¶łäčć€ïŒćč¶æćșćźç°èœŹæșçè„ćčČć»șèźźăć
šæć
±ćäșç« ïŒćć«ćŠäžïŒ 珏äžç« äž»èŠä»ç»èźșæćäœçèæŻćç 究æäčæćšïŒä»„ćç 究çèźșćæĄæ¶ă 珏äșç« éćŻčEBAYæè¶ŁććĄæšĄćŒïŒæç
§ćäžæšĄćŒćæ°çèźșçć±æŹĄïŒä»ććĄæšĄćŒçŻćąăććĄæšĄćŒèŠçŽ ă...eBayEachnet and Taobao are main competitors in Chinaâs E-commerce. eBayEachnet just took the lead in as earlier as year 2002, however, it was overwhelmed by Taobao and Paipai gradually, the leading was lost and the share market diminished very soon, as a result, it incorporated with Tom Online, a filial of Tom group limited company.Bearing in mind the theory of <Business Models Innovatio...ćŠäœïŒć·„ć知ççĄćŁ«éąçł»äžäžïŒçźĄçćŠéąć·„ć知çæèČäžćżïŒMBAäžćżïŒ_ć·„ć知ççĄćŁ«(MBA)ćŠć·ïŒ20041523
An integrative review: maternal engagement in the neonatal intensive care unit and health outcomes for U.S.-born preterm infants and their parents
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Background
This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 dia- betes and chronic kidney disease, cardiovascular disease, or both.
Methods
In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting\u2013enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level.
Results
The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pres- sures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, 656 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons).
Conclusions
The addition of aliskiren to standard therapy with renin\u2013angiotensin system block- ade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.
METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level.
RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, 656 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons).
CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful